Celemics, Inc.
Financials
Valuation Metrics
Celemics, Inc.'s Market Cap is ₩949B. At end of 2025 it was ₩304B. Ranked #1243 of 2,410 in KR market (top 52%), #674 of 1,631 on KOSDAQ (top 41%), #139 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 60%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 94.93B KRW | KR#1,243/2,410 Sec#139/231 |
| Revenue | 5.22B KRW | KR#2,328/2,410 Sec#195/231 |
| Net Income | -10.18B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 48.78B KRW | KR#2,213/2,410 Sec#202/231 |
| Net Assets | 30.39B KRW | KR#2,167/2,410 Sec#194/231 |
| Employees | 42 | KR#2,107/2,410 Sec#195/231 |
| Value | ||
| P/B | 3.16x | KR#2,161/2,410 Sec#176/231 |
| P/S | 18.42x | KR#2,328/2,410 Sec#185/231 |
| FCF Yield | -3.96% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -33.50% | KR#2,203/2,410 Sec#183/231 |
| ROA | -20.87% | KR#2,242/2,410 Sec#179/231 |
| Op. Margin | -74.41% | KR#2,265/2,410 Sec#167/231 |
| Revenue Growth | -16.21% | KR#2,062/2,410 Sec#188/231 |
| Financial Health | ||
| Debt Ratio | 60.48% | KR#1,098/2,410 Sec#130/231 |
| Total Debt | 16.24B KRW | KR#1,459/2,410 Sec#121/231 |
| FCF | -3.76B KRW | KR#1,432/2,410 Sec#114/231 |
| Cash | 37.10B KRW | KR#887/2,410 Sec#58/231 |
| Current Ratio | 22.92x | KR#21/2,410 Sec#9/231 |
| Performance | ||
| 1Y Return | 199.65% | KR#33/2,410 Sec#1/231 |
| 1M Return | -19.40% | KR#1,767/2,410 Sec#172/231 |
| From 52W High | -56.65% | KR#1,479/2,410 Sec#122/231 |
| 1Y MDD | -53.96% | KR#1,129/2,410 Sec#92/231 |
| Trading | ||
| Volume | 66,127 shares | KR#847/2,410 Sec#89/231 |
| Trading Value | 555.9M KRW | KR#779/2,410 Sec#83/231 |
| Foreign Own. | 1.10% | KR#1,990/2,410 Sec#196/231 |
| Per Share | ||
| EPS | -911 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,718 KRW | KR#1,931/2,410 Sec#151/231 |
Company Info
CeleMix was established in 2010 to manufacture and analyze basic pharmaceutical substances and biological preparations, and was specially listed on the KOSDAQ market in 2020 as a technology growth company. This venture company specializes as an NGS-based gene analysis technology platform, producing and selling MSSIC-based Target Capture Kits and BTSeq sequencing solutions. It develops DNA-related cloning technologies through technology convergence across biotechnology, nanotechnology, and information technology, supplying essential materials to various sectors. CeleMix is headquartered in Geumcheon-gu, Seoul.